Q BioMed IncOver The Counter Market:QBIO
- LAST PRICE0.0002
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0002
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Q BioMed Inc | 29.0K | 0.0x | --- |
Entia Biosciences Inc | 3.4K | 0.0x | --- |
Mera Pharmaceuticals Inc | 560.0 | 0.0x | --- |
Health Sciences Group Inc | 18.7K | 0.0x | --- |
Callitas Health Inc | 3.3K | 0.0x | --- |
Panacos Pharmaceuticals Inc | 50.0 | 0.0x | --- |
Company Information
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.
Contact Information
- Headquarters
- 366 Madison Ave Fl 3NEW YORK, NY, United States 10017-7110
- Phone
- 212-588-0022
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Denis Corin
- Chief Legal Officer, Director
- William Rosenstadt
- Director
- Rick Panicucci
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.0K |
|---|---|
Revenue (TTM) | $209.3K |
Shares Outstanding | 145.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.06 |
Book Value | $-0.05 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 120.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
